Global Ebola Virus Infection Market - 2024-2031

Global Ebola Virus Infection Market - 2024-2031

Global ebola virus infection market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.

Ebola virus disease formerly known as ebola haemorrhagic fever is a severe often fatal illness affecting humans and other primates. The virus is transmitted to people from wild animals such as fruit bats, porcupines and non-human primates and then spreads in the human population through direct contact with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids. Six different species of the virus have been found, but only four are known to cause disease in humans.

Preventive measures such as practicing good hand hygiene, avoiding contact with infected individuals or their bodily fluids and implementing infection control protocols are essential for controlling the spread of ebola virus infection. Vaccines have also been developed and deployed during outbreaks to help protect at-risk populations. Rapid identification, isolation and treatment of cases, along with effective public health interventions are crucial for containing outbreaks of this infection.

Market Dynamics: Drivers

Rising awareness about the virus

The rising awareness about the ebola virus is expected to drive the market over the forecast period. As awareness about the transmission and severity of ebola virus infection grows, there is likely to be increased demand for preventive measures such as vaccines, personal protective equipment and hygiene products. Individuals, healthcare facilities and governments may invest more in these measures to reduce the risk of ebola transmission.

For instance, in November 2022, the Kampala Capital City Authority (KCCA) launched citywide sensitization campaigns against Ebola disease in a bid to enhance efforts to prevent the virus in the country. KCCA has activated the Ebola response teams in the five divisions of Kampala to respond to any alert that is reported from communities, follow up on contacts reported from communities or as communicated by the Ministry of Health.

Rising awareness can foster international collaboration and funding for ebola-related initiatives. Governments, non-governmental organizations and global health agencies may allocate more resources to support research, surveillance and response efforts, particularly in regions with limited healthcare resources and high ebola burden.

For instance, in August 2021, Ivory Coast launched a mass awareness campaign in response to an Ebola outbreak in the West African country. The government and the World Health Organization (WHO) confirmed the outbreak in the country's largest city Abidjan, involving an 18-year-old woman hospitalized due to the virus after arriving from neighboring Guinea. The prevention and response plan has been designed in collaboration with global partners such as the World Health Organization and UNICEF.

Additionally, in March 2020, the Global Humanitarian and Development Foundation (GHDF), with funding from UNICEF, recently trained Angelique and nearly 2,000 of her colleagues in Bugesera and Nyanza Districts to spread information on the Ebola Virus Disease.

Restraints

Factors such as availability of limited treatment options, risks and complications associated with the ebola virus, limited regulatory requirements and unmet needs are the factors expected to hamper the ebola virus infection market.

For more details on this report - Request for Sample

Segment Analysis

The global ebola virus infection market is segmented based on type, treatment, route of administration, end-user and region.

The monoclonal antibodies segment accounted for approximately 51.4% of the ebola virus infection market share

The monoclonal antibodies segment is expected to hold the largest market share over the forecast period. There are two monoclonal antibody treatments for ebola virus disease, Inmazeb and Ebanga. Monoclonal antibodies work like the body’s natural antibodies and help fight off the infection while the body builds its own defenses. Inmazeb is a combination of three monoclonal antibodies and Ebanga is a single monoclonal antibody. These treatments have only been tested in Zaire ebolavirus infections.

For instance, in December 2020, Ridgeback Biotherapeutics LP cleared that the U.S. Food and Drug Administration approved Ebanga, a monoclonal antibody for the treatment of Ebola. Ebanga is now approved for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection). Ebanga is the only FDA-approved, single-injection Ebola treatment that is available in a lyophilized form.

Monoclonal antibodies have demonstrated therapeutic potential in treating ebola virus infection. They can be administered as a standalone therapy or in combination with other treatments, such as antiviral drugs or supportive care to improve clinical outcomes and reduce mortality. Due to the advantages offered by the monoclonal antibodies, many market players re focussing on the development of monoclonal antibody therapeutics.

For instance, on January 23, 2023, KBI Biopharma, Inc. entered into a subcontract with Mapp Biopharmaceutical, Inc. for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus. MBP134 is a two-antibody therapeutic candidate with demonstrated pan-ebolavirus efficacy in non-clinical studies. Alternative therapeutic approaches are often restricted to a single member of the Ebolavirus genus. In contrast, MBP134 confers unprecedented protection against antigenically diverse ebolaviruses at a single dosage.

Geographical Analysis

North America accounted for approximately 41.3% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies. This presence of major players in the region expanding the market by launching more therapeutics for the ebola virus followed by the FDA approvals.

For instance, on August 03, 2023, Merck cleared that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The vaccine was previously approved for use in individuals 18 years of age and older. The effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG) and/or blood or plasma transfusions is unknown. ERVEBO includes a contraindication for individuals with a history of a severe allergic reaction to any component of the vaccine, including rice protein.

In addition, there is an increasing research activities for the development of more advanced therapeutics for better treatment of ebola virus also helps to drive the market in the region. As the research activities increase, the therapeutics are developed more precisely by reducing complications, resulting in better patient outcomes.

For instance, in July 2023, the International AIDS Vaccine Initiative (IAVI) launched the first human trial of a Sudan Ebola virus vaccine, an investigational vesicular stomatitis virus (VSV) vector vaccine donated by Merck and licensed by IAVI. IAVI said the first-in-human phase 1 trial is funded by the US Biomedical Advanced Research and Development Authority (BARDA), which is part of the Department of Health and Human Services (HHS). It is the vaccine candidate's regulatory sponsor and is responsible for all future aspects of its clinical development, including how it measures up against IAVI's other Sudan Ebola vaccine, which uses the same virus vector but is made using a new production platform.

Competitive Landscape

The major global players in the ebola virus infection market include Ridgeback Biotherapeutics, LP, Merck & Co., Inc., Janssen Global Services, LLC, Regeneron Pharmaceuticals, Inc., KBI Biopharma, Soligenix, Inc., BioCryst Pharmaceuticals, Inc., GlaxoSmithKline plc, GeoVax Labs, Inc. among others. As there are only a few FDA-approved products, some above-mentioned companies have products in the pipeline.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global ebola virus infection market. The coronavirus disease 2019 (COVID-19) pandemic temporarily disrupted the clinical trials for ebola vaccines and therapeutics. Enrollment, data collection and trial implementation were challenged by lockdowns, travel restrictions and safety concerns, potentially delaying progress in ebola research and development. The pandemic raised public awareness about the importance of infectious disease prevention and control measures. This heightened awareness may translate into increased support for efforts to combat ebola virus infection.

Market Segmentation

By Type
• Zaire Ebolavirus
• Sudan Ebolavirus
• Taï Forest Ebolavirus
• Bundibugyo Ebolavirus
• Reston Ebolavirus
• Bombali Ebolavirus

By Treatment
• Monoclonal Antibodies
• Recombinant Viral Vaccines
• Others

By Route of Administration
• Intravenous
• Oral

By End-User
• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report??
• To visualize the global ebola virus infection market segmentation based on type, treatment, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of ebola virus infection market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global ebola virus infection market report would provide approximately 66 tables, 69 figures and 191 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies